New CPIP Policy Brief: An Unwise Move to Discriminate Against Pharmaceutical Patents

CPIP has published a new policy brief entitled An Unwise Move to Discriminate Against Pharmaceutical Patents: Responding to the UN’s Guidelines for Pharmaceutical Patent Examination. The brief, written by CPIP Senior Scholar and UMKC Professor of Law Chris Holman, analyzes the UN’s recent Guidelines for Pharmaceutical Patent Examination, which are influential in the policy debates … Continue reading “New CPIP Policy Brief: An Unwise Move to Discriminate Against Pharmaceutical Patents”

CPIP Scholars Examine the Flaws in the Term “Evergreening”

In their new paper, Evergreening of Pharmaceutical Exclusivity: Sorting Fact from Misunderstanding and Fiction, Professors Kristina Acri née Lybecker and Mark Schultz, along with CPIP John F. Witherspoon Legal Fellow David Lund, analyze how the term “evergreening” is used in the context of pharmaceuticals. After sorting through the vagaries and rhetorical excesses that restrict meaningful … Continue reading “CPIP Scholars Examine the Flaws in the Term “Evergreening””

The Common Economic Case for Patents and Copyrights

This is the second in a series of posts summarizing CPIP’s 2014 Fall Conference, “Common Ground: How Intellectual Property Unites Creators and Innovators.” The Conference was held at George Mason University School of Law on October 9-10, 2014.  Videos of the conference panels and keynote will be available soon. The opening panel of CPIP’s 2014 … Continue reading “The Common Economic Case for Patents and Copyrights”